Fig 1.

Dolutegravir median concentration versus time profiles by weight band and by pharmacokinetic sampling visit. First PK visit at a median (range) of 4.5 (4.0 to 5.6) weeks of dolutegravir based therapy, Second PK visit at a median (range) of 31.8 (29.6 to 34.1) weeks after starting dolutegravir-based therapy. The error bars represent interquartile ranges. Labeled dashed lines indicate adult reference geometric mean trough and peak concentration values on dolutegravir 50 mg once daily and 50 mg twice daily. Dashed line for the in vivo EC90 (0.32 mg/L) is also shown.